Oxycycloalkyl Camptothecin ADCs for Antitumor Activity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current antibody-drug conjugates based on camptothecin derivatives lack sufficient activity and appropriate toxicity profiles for clinical development, with no existing technologies investigating oxacyclyl-modified camptothecin and its derivatives.
Innovation Solution
Development of oxycycloalkyl-substituted camptothecin derivatives as antibody-drug conjugates, specifically designed with varying drug antibody ratios (DAR) and linker structures, targeting tumor-associated antigens using antibodies like anti-Her2, anti-Trop2, and others, and synthesized through specific chemical routes.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional camptothecin derivatives are used as antibody-drug conjugates, then the structure is relatively simple and synthesis is easier, but the antitumor activity is insufficient and toxicity profiles are not appropriate for clinical development
Solution Approach 1:
The patent modifies the camptothecin molecule by introducing oxacyclyl groups at specific positions (C-20 and/or C-10) with varying ring sizes (3-7 membered rings). This systematic variation of structural parameters (oxa group position, ring size, substitution patterns) enables optimization of both antitumor activity and toxicity profile while maintaining the core camptothecin scaffold for topoisomerase I inhibition
Solution Approach 2:
The patent creates composite molecular structures by combining camptothecin core with oxacyclyl substituents and linker-antibody conjugates. The ADC comprises camptothecin derivative (payload) + linker + antibody (targeting moiety), forming a composite therapeutic agent that integrates targeting, delivery, and cytotoxic functions into a single molecular system with improved therapeutic index
2Reliability
If oxycycloalkyl-substituted camptothecin derivatives are developed as ADCs, then antitumor effects are significantly improved, but the synthesis process becomes more complex
Solution Approach 1:
The patent segments the ADC development into distinct modular components: (1) camptothecin core synthesis, (2) oxacyclyl substituent preparation, (3) linker attachment, and (4) antibody conjugation. This segmentation allows each module to be optimized and characterized independently, facilitating systematic structure-activity relationship studies while managing synthetic complexity through modular assembly
Solution Approach 2:
The patent performs preliminary structural modifications by pre-installing oxacyclyl groups on the camptothecin core before antibody conjugation. This preliminary action creates a library of optimized payloads with improved pharmacological properties, which are then conjugated to antibodies using standard linker chemistry, thereby separating the complex payload synthesis from the conjugation step
3Reliability
If drug antibody ratio (DAR) is increased to improve therapeutic efficacy, then antitumor activity increases, but the molecular weight and complexity of the ADC increases
Solution Approach 1:
The patent systematically varies the drug-to-antibody ratio (DAR) as a key parameter to optimize therapeutic efficacy. By controlling the number of oxacyclyl-substituted camptothecin molecules conjugated to each antibody (creating ADCs with different stoichiometries), the patent identifies optimal drug load that maximizes antitumor activity while maintaining appropriate pharmacokinetic and safety profiles
Data Source
Figure 1~2
Figure 3~4
Figure 5~6
AI summary
An oxycycloalkyl-substituted camptothecin derivative used as an antibody-drug conjugate represented by formula (I) in the drug toxicity portion. The antibody-drug conjugate has a significant antitumor effect.